Is Cadrenal Therapeutics, Inc. (CVKD) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 51.7% / 30% | 0.2% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 0.0% / 33% | 51.7% / 33% | 0.2% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 0.0% / 33% | 99.0% / 33% | 0.4% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 51.7% / 33% | 0.2% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 0.0% / 33% | 99.0% / 33% | 0.4% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -468.0% | |
| Return on Assets (ROA) | -209.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$7M |
| Free Cash Flow | -$7M |
| Total Debt | $0 |
| Current Ratio | 3.0 |
| Total Assets | $10M |
Price & Trading
| Last Close | $5.24 |
| 50-Day MA | $6.95 |
| 200-Day MA | $10.48 |
| Avg Volume | 49K |
| Beta | 1.1 |
|
52-Week Range
$4.91
| |
About Cadrenal Therapeutics, Inc. (CVKD)
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company focuses on developing therapeutics for rare cardiovascular conditions. The company is developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Cadrenal Therapeutics, Inc. (CVKD) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Cadrenal Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Cadrenal Therapeutics, Inc.'s debt ratio?
Cadrenal Therapeutics, Inc.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are Cadrenal Therapeutics, Inc.'s key financial metrics?
Cadrenal Therapeutics, Inc. has a market capitalization of $12M. Return on equity stands at -468.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.